A ginsenoside derivative called 1C was shown to inhibit the Wnt pathway in LNCaP—a prostate cancer cell line—by decreasing the levels of β-catenin and TCF4, as well as target genes CCND1 and c-Myc, blocking its proliferation. The gene discussed is MYC; the disease is prostate carcinoma.